ADMA Biologics (ADMA) Tops Q2 EPS by 5c ; Offers Guidance

ADMA Biologics (NASDAQ: ADMA) reported Q2 EPS of $0.13, $0.05 better than the analyst estimate of $0.08. Revenue for the quarter came in at $107.2 million versus the consensus estimate of $86.44 million.

GUIDANCE:

ADMA Biologics sees FY2024 revenue of $400-445 million, versus the consensus of $357.5 million.

For earnings history and earnings-related data on ADMA Biologics (ADMA) click here.

You May Also Be Interested In

• Norwegian Cruise Line Holdings (NYSE: NCLH) PT Raised to $20 at UBS
• Appia Rare Earths names Kurt Radtke as president
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance